A MULTICENTER, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP TRIAL TO COMPARE THE EFFICACY AND SAFETY OF THE SUFENTANIL NANOTAB® PCA SYSTEM/15 MCG TO INTRAVENOUS PATIENT-CONTROLLED ANALGESIA WITH MORPHINE FOR THE TREATMENT OF ACUTE POST-OPERATIVE PAIN

Approval Date: 4/30/2012

Principal Investigator: Craig Hartrick, MD

The study is intended to show that the Sufentanil NanoTab PCA System is as effective as morphine intravenous patient-controlled analgesia (IV PCA) for treating pain after surgery. Each patient will use either the Sufentanil NanoTab PCA System or morphine IV PCA to treat their pain for at least 48 hours and up to 72 hours after surgery while in the hospital.

Eligibility:

Each study has its own guidelines to determine who can participate, called "eligibility criteria", with only the study doctor able to assess whether you meet all of the eligibility criteria.    More information can be found at  http://clinicaltrials.gov/ct2/show/NCT01539538.

Contact Person:
Cecile Pestano, RN, Research Coordinator
248-964-3440

Status of Clinical Trial:
open and enrolling